Auxly Cannabis Group (OTCMKTS:CBWTF) & Cleveland BioLabs (OTCMKTS:CBLI) Head-To-Head Review
Auxly Cannabis Group (OTCMKTS:CBWTF) and Cleveland BioLabs (NASDAQ:CBLI) are both small-cap finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.
This table compares Auxly Cannabis Group and Cleveland BioLabs’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Auxly Cannabis Group||-1,316.81%||-29.20%||-18.87%|
This table compares Auxly Cannabis Group and Cleveland BioLabs’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Auxly Cannabis Group||$580,000.00||550.22||-$51.68 million||N/A||N/A|
|Cleveland BioLabs||$1.14 million||13.08||-$3.61 million||N/A||N/A|
Cleveland BioLabs has higher revenue and earnings than Auxly Cannabis Group.
Institutional & Insider Ownership
4.0% of Cleveland BioLabs shares are held by institutional investors. 1.9% of Cleveland BioLabs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings and target prices for Auxly Cannabis Group and Cleveland BioLabs, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Auxly Cannabis Group||0||0||0||0||N/A|
Volatility & Risk
Auxly Cannabis Group has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Cleveland BioLabs has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.
Cleveland BioLabs beats Auxly Cannabis Group on 6 of the 10 factors compared between the two stocks.
Auxly Cannabis Group Company Profile
Auxly Cannabis Group Inc. operates as an integrated cannabis company. The company engages in the cultivation of cannabis; and development and distribution of cannabis products. It also offers products through its retail store. The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018. Auxly Cannabis Group Inc. was incorporated in 1987 and is based in Vancouver, Canada.
Cleveland BioLabs Company Profile
Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and an immunotherapy for oncology and other indications. Its development programs include CBLB612, which is in preclinical studies, a synthetic molecule that activates the toll-like heterodimeric receptor 2/6 and stimulated white blood cell generation; and that has completed Phase II for treating myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy. The company is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.
Receive News & Ratings for Auxly Cannabis Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auxly Cannabis Group and related companies with MarketBeat.com's FREE daily email newsletter.